The House today passed legislation that would suspend through 2022 tariffs on certain infant formula base powders used to make infant formula in the United States. Congress in July passed legislation (H.R.8351) suspending tariffs on imported infant formula through 2022. The Food and Drug Administration has allowed formula imports to help address a U.S. formula shortage, but tariffs have increased the retail cost of these products. The Department of Health and Human Services offers a webpage  to help health care providers and families locate formula.
 

Related News Articles

Headline
The AHA July 15 commented to Sens. Sheldon Whitehouse, D-R.I., and Bill Cassidy, R-La., responding to a request for information based on the Pay PCPs Act,…
Headline
The House Appropriations Committee July 10 voted 31-25 to approve legislation that would provide $185.8 billion in funding for the departments of Labor, Health…
Headline
The House Energy and Commerce Committee June 12 passed AHA-supported legislation during a markup of bills that passed the Health Subcommittee in May. The…
Headline
The AHA praised House and Senate leaders in letters June 12 for reintroducing the Improving Seniors’ Timely Access to Care Act, bipartisan legislation that…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Headline
The House Energy and Commerce Oversight and Investigations subcommittee June 4 hosted a hearing to discuss oversight of the 340B Drug Pricing Program. AHA sent…